http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-041198-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_382ccfc2ebebcaee15aa7cda4cee86bc |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F7-0812 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-424 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-541 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-428 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-498 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 |
| filingDate | 2003-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2005-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-041198-A1 |
| titleOfInvention | COMPOUND 2,3-DIHIDRO-6-NITROIMIDAZO [2,1-B] OXAXOL, AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT |
| abstract | oxygen); C1-6 phenylalkyl group (which may be Claim 1: A 2,3-dihydro-6-nitro compound substituted on the phenyl ring by at least one grimidazo [2,1-b] oxazole, characterized in that it is selected from the group which it consists of an atom represented by the general formula (1), the halogen polar form, a C1-6 alkyl group without a substituently active thereof, or a pharmaceutical or halogen substituted salt, and a C1-acceptable alkoxy group thereof, wherein R1 represents -6 unsubstituted or substituted by halogen); or gruun hydrogen atom or a C1-6 alkyl group, n rpo benzoyl (which may be substituted in the anecdote for an integer value 0 to 6, and R2 symbolizes phenyl at least for a group selected from the group represented by the formula general (A), a group consisting of a halogen atom, a gr (B), (C), (D), (E), (F) or (G) indicated plus advanced C1-6 alkyl unsubstituted or substituted and, in addition, R1 and - (CH2) nR2 can be linked to halogen, and a C1-6 alkoxy group unsubstituted or sr to each other with adjacent carbon atoms substituted by halogen); (Fda14) piperidinoa group itself through the nitrogen atoms, for C1-6 alkyl (which can be substituted in the anomaly of a spiro ring represented by the piperidine formula by a phenoxy group which can generally (H) of formula ( 14), a group represents having at least one unsubstituted alkyl group by the general formula (A): -OR3, wherein R3 rer or substituted by halogen as a substituent in present: A1) hydrogen atom; A2) alkyl phenyl ring group); (Fda15) C1-6 or C1-6 aminoalkyl group; A3) C1-6 alkoxy-C1-6 alkyl group; A4) grel which may have, as a substituent, at least one C1-6 phenylalkyl group (which may be substituted for a group selected from the group consisting of one or the phenyl ring at least by a group selected from the C1-6 alkyl group and a phenyl group , which may be the group consisting of a phenyl group having as a substituent a C1-6 alkoxy C1-6 alkoxy group, an unsubstituted C1-6 alkyl group or unsubstituted or substituted by halogen in the halogen substituted anyl, a C1-6 alkoxy group only phenyl; (Fda16) 1,2,3,6-tetrahydropyridylin group substituted or substituted by halogen, and a C1-6 alkyl group (which may be substituted on the a phenoxy which may have, as a substituent , 1,2,3,6-tetrahydropyridine at least one g for at least one C1-6 alkoxy group without replacing rupo phenyl which may have, as a substituent or substituted by halogen in the phenyl ring); A5, at least one C1-6 alkoxy group without substitue) C1-6 phenyl-alkyl group; A6) phenylalkenyl or halogen substituted group on the phenyl ring); C2-6 yl; A7) C1-6 alkylsulfonyl group; A8) group (Fda17) C1-6 naphthylalkyl group; (Fda18) benzenesulfonyl fl group which can be substituted C1-6 uorenyl alkyl; (Fda19) pyridylalkyl group by a C1-6 alkyl group; A9) C1-C1-6 alkanoyl group; (Fda20) C1-6 furylalkyl group (which may 6; A10) a group represented by the formula generates being substituted in the furan ring by a group (2), wherein R4 represents an unsubstituted or halogen substituted alkoxycarb phenyl group) ; C1-6 onyl; the phenyl C-alkoxycarbonyl groups (Fda21) C1-6 thienyl alkyl group; (Fda22) group ox1-6 (which can be substituted on the phenazolylC1-6 alkyl ring (which can be substituted for at least one group selected from the group qn the oxazole ring by a halogen atom or a gue consists of a C1-6 phenylalkoxy group, an unsubstituted or substituted phenyl grurupo C1-6 alkyl halogen unsubstituted or substituted by halo); (Fda23) C1-6 oxadiazolyl alkyl group (the halogen, and an unsubstituted C1-6 alkoxy group or its it can be substituted on the oxadiazole ring by halogen substituted); or C1-6 phenylalkyl group n unsubstituted or substituted by halo (which can be substituted on the phenyl ring geno); (Fda24) C1-6 pyrazylalkyl group ( at least one group selected from the group which cl may be substituted on the pyrazole ring by a group consisting of a phenyl-C 1-6 alkoxy group, a phenyl group group unsubstituted or substituted by halogen C 1-6 unsubstituted or substituted by halogen); (Fda25) benzot group C1-6 ienylalkyl (the cuo, and an unsubstituted or substituted C1-6 alkoxy group may be substituted on the benzothiophene ring used by halogen); A11) biphenyl alkoxycarbal group less for a group selected from the group than C1-6 conyl; A12) C1-6 benzoxazolyl alkyl group (it consists of a halogen atom and an alkoxy group which can be substituted on the C1-6 benzoxazoo ring without being substituted or substituted by halogen); (l at least for one oxo group as a substituent); A1Fda26) C1-6 thienyl alkyl group which may be substitu 3) benzoxazolyl group; or A14) oxazolyl alkylituid group in the thiophene ring with a C1-6 halogen atom (which can be substituted in the ring; (Fda27) C1-6 benzothiazolyl alkyl group; (Fda28 oxazol at least by a group selected from the group) benzofurylalkyl group C1-6 which may be spo consisting of a phenyl group and alkyl group substituted on the benzofuran ring by a C1-6 atom as a substituent), a group represented by halogen; (Fda29) C1-6 indolinylalkyl group (elr the general formula (B): -SR5, where R5 represents which in the indolite ring can be substituted by a tetrazolyl group (which can be substituted less by a group selected from the group that listed on the tetrazole ring by a Cnsiste alkyl group of a C1-6 alkyl group and an oxo group); (1-6 or phenyl group which may have an atom of Fda30) C1-6 benzoxazolyl alkyl group (which may be halogen as a substituent), or benzoxazode group to be substituted on the benzoxazole ring, a group represented by the general formula by a group selected from the group consisting of (C): -COOR6, wherein R6 represents a group from a halogen atom, a C1-6 alkyl group, and C1-6 yl, a carbamoyloxy group represented by an oxo group); (Fda31) C1-6 chromenylalkyl group; the general formula (D): -OOCNR7R8, wherein R7 and (Fda32) group 1,2,3,4-tetrahydroquinolilalkyl CR8 each that is the same or different represents cu1-6 (which can be substituted in the ring of any from: D1) hydrogen atom; D2) alkyquinoline group at least one group selected from the C1-8 guyl; D3) C1-6 alkyl group substituted by a group consisting of a C1-6 alkyl group and a general purpose; D4) C1-6 alkoxycarbonyl-C1-upo oxo) group; (Fda33) C1-6 thiazolylalkyl group (c6; D5) C3-8 cycloalkyl group; D6) phenylalkyl group may be substituted in the thiazole ring to C1-6 meuyl (which may be substituted in the anilnes by a group selected from the group consisting of phenyl at least by a group selected from the group of a halogen atom, a group unsupported phenyl consisting of a halogen atom, a group constituted or substituted by halogen, and a C1-6 alkyl alkyl group unsubstituted or substituted by C1-6 halogen); or (Fda34) C1-6 tetrazolylalkyl group, and an unsubstituted C1-6 alkoxy group or its (which can be substituted on the tetrazotituted ring by halogen); D7) phenyl group (which pl by a group selected from the group consisting of being substituted on the phenyl ring by 1 to 3 of a phenyl group unsubstituted or substituted by groups selected from the group consisting of a halogen and a C1-6 alkyl group ); (Fd37) a halogen group, a C1-6 alkyl group without a substitute represented by the general formula (Fe): -Z-NR3 having or substituted by halogen, a 2R33 alkoxy group, where Z represents -C = O or -C = S, and R32 and RC1-6 unsubstituted or substituted by halogen, a g33 each equal or different represents any C1-6 alkanoyl group, a carboxyl group, a group of: (Fe1) hydrogen atom; (Fe2) C1-6 alkylalkoxycarbonyl group, a C1-6 phenylalkoxycarbonyl group; (Fe3) C3-8 cycloalkyl group; (Fe4) C1-6 group, a carbamoyl group, a C1-6 alkylcarbam phenyl group (which can be substituted C1-6 eoyl, an aminosulfonyl group and a phenyl ring morphn group at least by a selectioninool group); D8) naphthyl group; D9) pyridyl group; and Given the group consisting of a halogen atom10) R7 and R8 can be linked together with l, an unsubstituted or substituted C1-6 alkyl group or nitrogen atoms adjacent thereto or by halogen, and a C1 alkoxy group -6 without substitute through other hetero atoms or carbon atoms, uir or substituted by halogen); (Fe5) phenyl group to form a C2-6 illustlkenyl saturated heterocyclic group (which may be substituted on the rado in any of (D10-1) to (D10-3) indicated phenyl ring at least by a group selected below, or condensed heterocyclic group of the group consisting of a halogen atom, an e benzene illustrated in any of (D10-4) to (D1 C1-6 alkyl group unsubstituted or substituted by 0-7) indicated below: (D10-1 ) piperhalogen group and an unsubstituted C1-6 alkoxy or azinyl group represented by the general formula (Da) substituted by halogen); (Fe6) phenyl group (ce the formula (3), wherein R9 represents: (Da1) may be substituted in the phenyl ring to the hydrogen atom; (Da2) C1-6 alkyl group; (Da3) nos for a group selected from the group consisting of C1-6 phenylalkyl group (which may be a halogen atom substitute, a C1-6 alkyl group in the phenyl ring at least one group unsubstituted or substituted by halogen, and a group group of the group consisting of an unsubstituted or halogen substituted C1-6 alkoxy halo atom, an unsubstituted or substituted C1-6 alkyl group, and an unsubstituted or substituted C1-6 alkoxy group by halogen, and a C1-6 alkoxy group not replaced by halogen); and (Fe7) R32 and R33 may be substituted or substituted by halogen); (Da4) group f |
| priorityDate | 2002-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 71.